Results 1 to 10 of about 110,212 (273)
Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid -- a meta-analysis of randomised and observational trials of over 30.000 patients. [PDF]
PLoS ONE, 2013 BackgroundTo compare the effect of aprotinin with the effect of lysine analogues (tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients: low, intermediate and high risk of cardiac surgery.Methods and findingsWe ...
Patrick Meybohm +3 more
doaj +4 more sources
Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundThere is still uncertainty about the safety of aprotinin for coronary artery bypass graft surgery. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral versus single internal thoracic artery grafting. Many
Umberto Benedetto +7 more
doaj +9 more sources
Aprotinin Inhibits SARS-CoV-2 Replication
Cells, 2020 Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S ...
Denisa Bojkova +2 more
exaly +3 more sources
Aprotinin in high-risk isolated coronary artery bypass graft patients: a 3-year propensity matched study [PDF]
Journal of Cardiothoracic SurgeryBackground Aprotinin, a serine protease inhibitor, has been used variably in cardiac surgery amidst ongoing debates about its safety following several previous studies.
Rishab Makam +5 more
doaj +2 more sources
TH Open, 2021 Background Aprotinin is a broad-acting serine protease inhibitor that has been clinically used to prevent blood loss during major surgical procedures including cardiac surgery and liver transplantation.
Ton Lisman +3 more
doaj +1 more source
The Journal of Thoracic and Cardiovascular Surgery, 2012 In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery as an adjunct to decrease postoperative bleeding and complications.
DeAnda, Abe, Spiess, Bruce D.
openaire +2 more sources
npj Regenerative Medicine, 2022 The biomaterial fibrin is widely used as a clinical tissue sealant in surgery. In preclinical research, fibrin is also extensively studied as a carrier material for growth factor delivery.
Jialu Liu +4 more
doaj +1 more source
Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo
Scientific Reports, 2021 Influenza viruses cause significant morbidity and mortality worldwide. Long-term or frequent use of approved anti-influenza agents has resulted in drug-resistant strains, thereby necessitating the discovery of new drugs. In this study, we found aprotinin,
Eun-Jung Song +8 more
doaj +1 more source
Frontiers in Bioengineering and Biotechnology, 2022 In tissue engineering, cell origin is important to ensure outcome quality. However, the impact of the cell type chosen for seeding in a biocompatible matrix has been less investigated.
Elea Boucard +5 more
doaj +1 more source
The safety and efficacy of antifibrinolytic therapy in neonatal cardiac surgery. [PDF]
PLoS ONE, 2015 Neonates undergoing open-heart surgery are particularly at risk of postoperative bleeding requiring blood transfusion. Aprotinin has attained high efficacy in reducing the requirement for a blood transfusion following a cardiopulmonary bypass, but is ...
Chih-Yuan Lin +6 more
doaj +1 more source